Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout

Resumen detallado
Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML) - Comprehensive…
- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)
- Comprehensive Part A data readout remains on track for the first quarter of 2027, supporting optimal dose selection and planned initiation of Part B
- Annamycin's differentiated cardiac safety profile further supported by peer-reviewed analysis of 90 patients across five clinical trials, with no evidence of clinical or subclinical cardiotoxicity at first interim analysis
- New preclinical findings suggest Annamycin may help turn immunologically "cold" pancreatic tumors "hot," supporting potential combination treatment approaches
HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported on Friday the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML).
Moleculin continues to advance its lead clinical program following completion of treatment for all 90 patients in Part A of the MIRACLE trial. The Company remains on track to report comprehensive Part A data in the first quarter of 2027. These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.
"We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.
"What gives us confidence as we approach this readout is the…
Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)




